New cancer chemotherapy drugs in Europe

Arcamone, F., Benardi, L., Giardino, P., Patelli, B., Di Marco, A., Casazza, A. M., Pratesi, G., Reggiani, P.: Synthesis and antitumour activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin and their β-anomers. Cancer treat. Rep. 60, 829–833 (1976) Astaldi, G.: Peptichemio: a multifaceted antiblastic drug. Wadley med. Bull. 5, 303–326 (1975) Atassi, G., Tagnon, H. J.: Comparison of Adriamycin with the DNA-Adriamycin complex in chemotherapy of L1210 leukemia. Europ. J. Cancer 10, 399–403 (1974) Atassi, G., Tagnon, H. J.: R 17.934-NSC 238. 159: a new antitumour drug. I. Effect on experimental tumors and factors influencing effectiveness. Europ. J. Cancer 11, 599–607 (1975) Atassi, G., Duarte-Karim, M., Tagnon, H. J.: Comparison of Adriamycin with DNA-Adriamycin complex in chemotherapy of experimental tumors and metastases. Europ. J. Cancer 11, 309–316 (1975) Bachmann, E., Weber, E., Zbinden, G.: Effects of seven anthracyclin antibiotics on electrocardiogram and mitochondrial function of rat hearts. Agent and Actions 5 (4), 383–393 (1975) Bakowski, M. T.: ICRF 159(+)1,2-di-(3,5-dioxopiperazin-1-yl)-propane NSC-129,943; Razoxane. Cancer treat. Rev. 3, 95–107 (1976) Begg, A. C., Sheldon, P. W., Forster, J. L.: Demonstration of hypoxic cell radiosensitization in solid tumours by metronidazole. Brit. J. Radiol. 47, 399–404 (1974) Brandt, L., Könyves, I.: Therapeutic effect of prednimustine (Leo 1031) in various types of leukemia. Europ. J. Cancer 13, 393–398 (1977) Brandt, L., Könyves, I., Möller, T. R.: Therapeutic effect of Leo 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. I. Acta med. scand. 197, 317–322 (1975) Brazhnikova, M. G., Konstantinova, N. V.: Antitumor antibiotic nocamycin: isolation and characterization (Abstract 566). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Burchenal, J. H., Kalaher, K., O'Toole, T., Chisholm, J.: Lack of cross-resistance between certain platinum coordination compound in mouse leukaemia. Cancer Res. 37, 3455–3457 (1977) Buroker, T., Baker, L., Correa, J., Schwartz, L. A., Vaitkevicius, V. K.: Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers. Cancer treat. Rep. 61, 463–467 (1977) Calvert, A. H., Price, L. A.: DDMP (2,4-diamino-3′,4′-dichlorophenyl-6-methylpyrimidine) in the treatment of metastatic hypernephroma (Abstract 517). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Casazza, A. M., Di Marco, A., Bertazzoli, C., Formelli, F., Giuliana, G.: Antitumour activity, toxicity and pharmacological properties of 4′-epiadriamycin (Abstract 502). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Cattan, A., Pourny, C., Carpentier, Y., Cattan, E., Barouch, M.: Antimetastasis effect of two derivatives of epipodophyllotoxin in mice. Europ. J. Cancer 12, 797–805 (1976) Chauvergne, J., Durand, M.: Essai de chimiothérapie de tumeurs solides par la rubidazone. Bordeaux med. 12, 1257–1259 (1973) CMEA studies: Joint clinical study of new antineoplastic agents phase (III). In: Antitumour Drug Therapy Reports 3, 37–39 (1977) Colvin, M., Brundrett, R. B., Kan, M. N. N., Jardine, I., Fenselau, C.: Alkylating properties of phosphoramide mustard. Cancer Res. 36, 1121–1126 (1976) Connors, T. A., Braddock, P. D., Khokhar, A. R., Tobe, M. L.: New platinum complexes with antitumour activity. Chem. Biol. Interactions 5, 415–424 (1972) Connors, T. A., Cumber, A. J., Ross, W. C. J., Clarke, S. A., Mitchley, B. C. V.: Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine. Cancer treat. Rep. 61, 927–928 (1977) Conroy, P. J., Nodes, J. T., Slater, T. F., White, G. W.: The inhibitory effects of a 4-hydroxy-pentenal: cysteine adduct against sarcoma 180 cells in mice. Europ. J. Cancer 13, 55–63 (1977) Csetényi, J., Hegedüs, L., Szamel, I., Bodrogi, I., Kanyar, B., Kerpel-Fronius, S., Eckhardt, S.: Human pharmacokinetic studies of Lycurim (Abstract 612). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 De Barbieri, A., Di Vittorio, P., Perrone, F., Mangeri, M., Agosteo, A. P. Zappa, M., Temelcon, O.: A new class of antitumour glycopeptides (Abstract 521). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 De Brabander, M., Van de Veire, R., Aerts, F., Geuens, G., Desplenter, L., De Cree, J., Borders, M., Janssen, P. A. J.: R 17934: a new synthetic anticancer drug interfering with microtubules. Chemotherapy 8, 121–127 (1976) De Brabander, M., Van de Veire, R. M. L., Aerts, F. E. M., Borgers, M. J. M., Janssen, P. A. J.: The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate (R 17934; NSC 238.159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro. Cancer Res. 36, 905–916 (1976) De Brabander, M., Geuens, G., Van de Veire, R., Thone, F., Aerts, F., Desplenter, L., De Cree, J., Borgers, M.: The effects of R 17934, a new antimicrotubular substance on the ultrastructure of neoplastic cells in vivo. Europ. J. Cancer 13, 511–528 (1977) Depres-De Campeneere, D., Masquelier, M., Trouet, A.: Compared activity of daunorubicin and two derivatives on L1210 leukaemia in vitro and in vivo (Abstract 494). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Di Marco, A., Casazza, A. M., Pratesi, G.: Enhancement by Tween 80 of the antitumour activity of adriamycin on experimental mouse tumours. I.R.S.C. Med. Sci. 4, 452 (1976) Di Marco, A., Casazza, A. M., Pratesi, G.: Antitumour activity of 4-demethoxydaunorubicin administered orally. Cancer treat. Rep. 61, 893–894 (1977) Dombernowsky, P., Nissen, N. I.: Combination chemotherapy with 4'demethylepipodophyllotoxin-9-(4,6-O-ethylene-β-d-glucopyrasonide), VP 16213 in L1210 leukaemia. Europ. J. Cancer 12, 181–188 (1976) Eagan, R. T., Moertel, C. G., Hahn, R. G., Schutt, A. J.: Phase I study of a five day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313). J. nat. Cancer Inst. 56, 179–181 (1976) Eckhardt, S., Hindy, I., Farkas, E.: Clinical pharmacological studies with formyl-leurosine in malignant diseases, p. 451. In: Proceedings of 9th International Congress of Chemotherapy, London (Eds. K. Hellman and T. A. Connors). New York: Plenum Press 1976 Emanuel, N. M., Konovalova, N. P., Djachkovskaya, R. F.: Antitumour activity of 1,2-bis-diacetyl ethane. Cancer treat. Rep. 60, 1601–1604 (1976) EORTC Clinical Screening Group: Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas and solid tumours. Brit. med. J. 3, 199–202 (1973) EORTC Clinical Screening Group: Essai thérapeutique phase II de l'ifosfamide dans les hématosarcomes et les tumeurs solides. Sem. Hôp. Paris 51, 7–10 (1975) EORTC Clinical Screening Group: A phase II clinical trial of prednimustine. Biomedicine 27, 158–161 (1977a) EORTC Clinical Screening Group: A phase II clinical trial of cytembena. Biomedicine 26, 392–395 (1977b) EORTC Clinical Screening Group: A phase II clinical trial of peptichemio. Biomedicine 27, 290–294 (1977c) EORTC Cooperative Group for Leukaemias and Haematosarcomas: Clinical screening of epipodophyllotoxin VM 26 in malignant lymphoma and solid tumours. Brit. med. J. 2, 744–748 (1972) EORTC Screening and Pharmacology Group: Hexitol derivatives; screening and kinetics. In: Proceedings of a Conference on Galactitol Derivatives, Budapest, September 1977 (in press, 1978) Farkas, E., Eckhardt, S.: Clinical investigations with formyl-leurosine, p. 457. In: Proceeding of 9th International Congress of Chemotherapy, London (Eds. K. Hellman and T. A. Connors). New York: Plenum Press 1976 Fenelly, J. J.: The role of treosulfan in ovarium carcinoma (Abstract 554). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Fiebig, H. H., Eisenbrand, G., Zeller, W. J., Deutsch-Wenzel, T.: Water soluble derivatives and bifunctional analogs of the anti-cancer agent 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU). Europ. J. Cancer 13, 937–945 (1977) Foster, J. L., Conroy, P. J., Searle, A. J., Willson, R. L.: Metronidazole (flagyl): characterization as a cytotoxic drug specific for hypotoxic tumour cells. Brit. J. Cancer 33, 485–490 (1976) Fowler, J. F., Sheldon, P. W., Denekamp, J., Field, S. B.: Optimum fractionation of the C3H mouse mammary carcinoma using X-rays, the hypoxic-cell radiosensitizer R0-07-0582 or fast neutrons. Int. J. Radiat. Oncol. Biol. Phys. 1, 579–592 (1976) Garibjanian, B. T., Jonson, R. K., Kline, I., Vadlamudi, S., Gang, M., Venditti, J. M., Goldin, A.: Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Cancer treat. Rep. 60, 1347–1361 (1976) Geran, R. I., Congleton, G. F., Dudeck, L. E., Abbott, B. J., Gargus, J. L.: A mouse ependymoblastome as an experimental model for screening potential antineoplastic drugs. Cancer Chemother. Rep. 4 (part 2), 53–87 (1974) Gershanovich, M. L.: Clinical data on the antitumour activity of hydrazine sulfate. Cancer treat. Rep. 60, 933–935 (1976) Gosalves, M., Canero, R. G., Blanco, M.: A screening for selective anticancer agents among plant respiratory inhibitors. Europ. J. Cancer 12, 1003–1009 (1976) Hansen, B., Fex, H., Holmberg, K., Högberg, B., Jensen, G., Könyves, I.: Some esters of progestins and alkylating agents and their cytostatic properties (Abstract 506). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Harrap, K. R., Riches, P. G., Gilby, E. D., Sellwood, S. M., Wilkinson, R., Könyves, I.: Studies on the toxicity and antitumour activity of predimustine, a prednisolone ester of chlorambucil. Europ. J. Cancer 13, 873–881 (1977) Hayat, M., Mathé, G., Janot, M. M., Potier, P., Dat-Young, N., Cavé, A., Sevenet, T., Kan-Fan, C., Poisson, J., Miet, J., Le Men, J., Le Goffic, F., Fouyette, A., Ahond, A., Dalton, L. K., Connors, T. A.: Experimental screening of 3 forms and 19 derivatives or analogs of ellipticine: oncostatic effect on L1210 leukaemia and immunosuppressive effect of 4 of them. Biomedicine 21, 101–106 (1974) Hill, B. T., Price, L. A., Harrison, S. I., Goldie, J. H.: Studies on the transport and distribution of diaminopyrimidines in L5178Y lymphoblasts in cell culture. Biochem. Pharmacol. 24, 535 (1975) Hill, B. T., Price, L. A., Harrison, S. I., Goldie, J. H.: The difference between “selective folinic acid protection” and “folinic acid rescue” in L5178Y cells culture. Europ. J. Cancer 13, 861–871 (1977) Hill, J. M., Loeb, E., Pardue, A. S., Khan, A., Hill, N. O., King, J. J., Hill, R. W.: Platinum coordination compounds in the treatment of acute leukaemia and other malignant diseases with particular reference to malonato 1,2-diaminocyclohexane platinum. J. clin. Hematol. Oncol. 7, 671–710 (1977) Hoebeke, J., Van Nijen, G., De Brabander, M.: Interaction of oncodazole (R 17.934), a new antitumoral drug, with rat brain tubulin. Biochem. biophys. Res. Commun. 69, 319–324 (1976) Hohorst, H. J., Peter, G., Struck, R. F.: Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo. Cancer Res. 36, 2278–2281 (1976) Husson, H. P., Thevenet, T., Kan, C., Pottier, P.: Alangium vitiense extracts. phytochemistry (in press, 1977) Imbach, J. L., Montero, J. L., Moruzzi, A., Serrou, B., Chenu, E., Hayat, M., Mathé, G.: The oncostatic and immunosuppressive actions of new nitrosourea derivatives containing sugar radicals. Biomedicine 23, 410–413 (1975) International Holoxan Symposium. 21.–23. 3. 1977, Düsseldorf. Proceedings to be published in 1978 Israel, M., Modest, E. J., Frei, E.: N-trifluoroacetyl adriamycin-14-valerate, an analog with greater experimental antitumour activity and less toxicity than adriamycin. Cancer Res. 35, 1365–1368 (1975) Jacquillat, Cl., Weil, M., Gemon-Auclerc, M. F., Izrael, V., Bussel, A., Boiron, M., Bernard, J.: Clinical study of rubidazone (22.050RP) a new daunorubicin-derivated compound, in 170 patients with acute leukemias and other malignancies. Cancer 37, 653–659 (1976) Jager, R. de., Brugarolas, A., Hansen, H., Cavalli, F., Wennerholm, A., Kenis, Y., Alberto, P.: Oral dianhydrogalactitol (DAG): phase I-II study. Proc. Amer. Assoc. Clin. Oncol. 18, 295 (abstract C-114), 1977 Johnson, R. K., Garibjanian, B. T., Houchens, D. P., Kline, I., Gaston, M. R., Syrkin, A. B., Goldin, A.: Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice. Cancer treat. Rep. 60, 1335–1345 (1976) Jurct, P., Tanguy, A., Gerard, A., Le Talaer, J. Y., Dat-Xuong, N., Le Pecq, J. B., Paoletti, C.: Therapeutic effect of 9-hydroxy-2-(N)-Methyl-Ellipticine (NSC-264137) in human advanced cancers: preliminary results. Presented at EORTC Early Clinical Trials Meeting, Copenhagen, June 1977. To be published in 1978 Kaufman, J. H., Hanjura, G. L., Mittelman, A., Aungst, C. W., Murphy, G. P.: Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Cancer Treat. Rep. 60, 277–279 (1976) Kohn, K. W., Waring, M. J., Glaubiger, D., Friedman, C. A.: Intercalative binding of ellipticine to DNA. Cancer Res. 35, 71–76 (1975) Könyves, I., Nordenskjöld, B., Plym Forshell, G., de Schrijver, A., Westerberg-Larsson, H.: Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Europ. J. Cancer 11, 841–844 (1975) Krishan, A., Israel, M., Modest, J., Frei, E.: Differences in cellular uptake and cytofluorescence of adriamycine and N-trifluoacetyl adriamycin-14-valerate. Cancer Res. 36, 2108–2110 (1976) Lasnitzki, I.: Inhibition of precancerous changes by vitamin A and its structural analogues in organ culture (Abstract 588). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Lelieveld, P.: Cell killing effectiveness of hycanthone. Europ. J. Cancer 13, 897–898 (1977) Lelieveld, P.: Data reported at EORTC Sereening and Pharmacology Group meeting 1977. To be published in 1978 Le Men, J., Hayat, M., Mathé, G., Guillon, J. C., Chenu, E., Humblot, E. Masson, Y.: Methoxy-90ellipticine lactate. I. Experimental study. Europ. J. clin. biol. Res. 15, 534–538 (1970) Lenaz, L., Necco, A., Dasdia, T., Di Marco, A.: Biologic activity of some adriamycin derivatives. Cancer Chemother. Rep. 58, 769–776 (1976) Le Pecq, J. B., Dat-Xuong, N., Gosse, C., Paoletti, C.: A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in a series of DNA intercalating drugs. Proc. nat. Acad. Sci. (Wash.) 71, 5078–5082 (1974) Le Pecq, J. B., Gosse, C., Dat-Xuong, N., Paoletti, C.: Deux nouveaux dérivés antitumoraux: l'hydroxy-9-methyl-2-ellipticinium (acétate) et l'hydroxy-9-diméthyl-2,6-ellipticinium (chlorure). Action sur la leucémie L1210 de la souris. C.R. Acad. Sci. (Paris) 281, 1365–1367 (1975) Le Pecq, J. B., Gosse, C., Dat-Xuong, N., Cros, S., Paoletti, C.: Antitumor activity of 9-hydroxyellipticine (NSC 210717) on L1210 mouse leukemia and the effect of route of injection. Cancer Res. 36, 3067–3076 (1976) Levin, V. A., Freeman-Dove, M. A., Maroten, C. E.: Dianhydrogalactitol (NSC-132313): Pharmacokinetics in normal and tumorbearing rat brain and antitumor activity against three intracerebral rodent tumors. J. nat. Cancer Inst. 56, 535–539 (1976) Lutz, D., Böhnel, J., Stacher, A.: Prednimustine treatment in chronic lymphocytic leukaemia (Abstract 505). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Maral, R.: Experimental activities of benzoylhydrazone daunorubicine (rubidazone). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Maral, R., Ducep., J. B., Frage, D., Ponsinet, G., Reisdorf, D.: Preparation et activité antitumorale expérimentale d'un nouvel antibiotique semisynthétique: la diethoxy-14-daunorubicine. C.R. Acad. Sci. (Paris) (in press, 1977) Mathé, G., Hayat, M., de Vassal, F., Schwarzenberg, L., Schneider, M., Schlumberger, J. R., Jasmin, C., Rosenfeld, C.: Methoxy-9-ellipticine lactate. II. Clinical screening. Europ. J. clin. biol. Res. 15, 541–545 (1970) Mathé, G., Schwarzenberg, L., Pouillart, P., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., De Vassal, F.: Two epipodophyllotoxin derivatives VM26 and VP16213, in the treatment of leukemias, hematosarcomas and lymphomas. Cancer 34, 985–992 (1974) Mathé, G., Machover, D.: Intra tumour injection of bleomycin (in press, 1977a) Mathé, G., Hayat, M., Husson, P., Chenu, E.: Oncostatic effects of alangium vitiense extracts, ICIG-EORTC 1131, 1186 and 1207 on lymphoid tumours. Cancer Res. (in press, 1977b) Mathé, G., Misset, J. L., De Vassal, F., Hayat, M., Machover, D., Belpomme, D., Schwarzenberg, L., Ribaud, P., Musset, M., Jasmin, C.: Phase II clinical trial with vindesine for remission induction in acute leukaemia, blastic crisis of chronic myeloid leukaemia, lymphosarcoma and Hodgkin's disease. Absence of cross-resistance with vincristine. Medical Oncology 3, S21 (abstract 51) (1977c) and Cancer Treat. Rep. (in press, 1978a) Mathé, G., Serrou, B., De Vassal, F., Misset, J. L., Schwarzenberg, L., Hayat, M., Machover, D., Ribaud, P., Belpomme, D., Jasmin, C., Musset, M.: Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours. Biomedicine 27, 294–297 (1977d) Mathé, G., De Vassal, F., Misset, J. L., Schwarzenberg, L., Hayat, M., Machover, D., Ribaud, P., Belpomme, D., Jasmin, C., Musset, M.: Preliminary results of phase I and II clinical trials of RPCNU a new nitrosourea derivative. Cancer Chemother. Pharmacol. (in press, 1978b) Mathé, G., Hayat, M., Jasmin, C., Halle-Pannenko, O., Serrou, B., Chenu, E., Bourut, C., Imbach, J. L., Montero, J. L., Moruzzi, A.: Further experimental study of the oncostatic action and side effects of new nitrosourea derivatives. Cancer Chemother. Pharmacol. (in press, 1978c) Matter, A., Bollag, W.: A fine structural study on the therapeutic effect on an aromatic retinoid on chemically-induced skin papillomas of the mouse. Europ. J. Cancer 13, 831–838 (1977) Misset, J. L., Pouillart, P., Belpomme, D., Schwarzenberg, L., Delgado, M., Gil, M., Jasmin, C., Hayat, M., Mathé, G.: Combination chemotherapy with adriamycin, VM26, cyclophosphamide and prednisone in lymphosarcomas and reticulosarcoma. Europ. J. Cancer 13, 411–414 (1977) Mittelman, A., Shukla, S. K., Welvaart, K., Murphy, G. P.: Oral estramustine (NSC-89199) in the treatment of advanced (stage D) carcinoma of the prostate. Cancer Chemother. Rep. 59, 219–223 (1975) Mittelman, A., Shukla, S. K., Murphy, G. P.: Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J. Urol. 115, 409–412 (1976) Mittelman, A., Catane, R., Murphy, G. P.: New steroidal alkylating agents in advances stage D carcinoma of the prostate. Cancer treat. Rep. 61, 307–310 (1977) Möller, T. R., Brandt, L., Könyves, I., Lindberg, K. G.: Therapeutic effect of Leo 1031, an alkylating corticosteriod ester, in lymphoproliferative disorders, II. Acta med. scand. 197, 323–327 (1975) Németh, L., Institoris, L., Somfai, S., Gál, F., Sugár, J., Csuka, O., Szentirmay, Z., Kellner, B.: Pharmacologic and antitumor effect of 1,2:5,6-dianhydrogalactitol (NSC-132313). Cancer Chemother. Rep. 56, 593–602 (1972) Newman, H., Vodinelich, L., Potter, C. W.: The effects of 1-β-d-ribofuranosyl-2,2,4-triazole-3-carboxamide (ribavirin) on the transplanted tumours of animal. Europ. J. Cancer. 13, 821–830 (1977) Nillius, A., Könyves, I.: Oral Estracyt® (estramustine phosphate) in the treatment of advanced carcinoma of the prostate, p. 469. In: Proceedings 9th International Congerss Chemotherapy, London (Eds. K. Hellman and T. A. Connors). New York: Plenum Press 1976 Nilsson, T., Jönsson, G.: Clinical results with estramustine phosphate (NSC-89199): a comparison of the intravenous and oral preparations. Cancer Chemother. Rep. 59, 229–232 (1975) Oki, T., Matsuzawa, Y., Yashimoto, A., Numata, K., Kitamura, I., Hori, S., Takamatsu, A., Umezawa, H., Ishizuta, M., Naganawa, H., Suda, H., Hamada, M., Takenchi, T.: New antitumor antibiotics aclacinomycins A and B. J. Antibiot. (Tokyo) 28, 830–840 (1975) Ossewaarde, T.: Data reported at EORTC Screening and Pharmacology Group meeting, 1977. To be published in 1978 Oswald, H.: Potentiated chemotherapeutic activity of 3,6-diamino-10-methylacridinium by combination with glycine or dl-β-alanine on the Ehrlich carcinoma. Arzneimittel-Forsch. 25, 1608–1609 (1975) Pályi, I.: Survival and phase sensitivity of hela cells treated with dianhydrogalactitol (NSC-132313). Cancer Chemother. Rep. 59, 493–499 (1975) Panasci, L. C., Green, D. C., Nagourney, R., Fox, P., Schein, P. S.: A structure-activity analysis of chemical and biological parameters of chloro-ethyl nitrosoureas in mice. Cancer Res. 37, 2615–2618 (1977) Paoletti, M. C., Cros, S., Sorbara, M. M.R., Gosse, C., Tollon, Y., Moisand, C.: Toxicology. Etudes sur la toxicité de la 9-hydroxyellipticine. C.R. Acad. Sci. (Paris) 278, 1437–1440 (1974) Pham-Huu-Chanh, M. M., Sorbara, R., Dat-Xuong, N., Le Pecq, J. B., Paoletti, C.: Pharmacologie. Actions cardio-vasculaires et toxicités de l'hydroxy-9-ellipticine chez le chien. C.R. Acad. Sci. (Paris) 279, 1039–1042 (1974) Pouillart, P., Mathé, G., Hoang, Thy, T., Lheritier, J., Poisson, M., Huguenin, P., Gautier, H., Morin, P., Parrot, R.: Treatment of malignant gliomas in adults using a combination of adriamycin, VM26 and CCNU: result of a type II trial. Europ. J. Cancer 13, 419–424 (1977) Pratesi, G., Casazza, A. M., Di Marco, A.: Antitumor activity of N-trifluoro-aceto-acetyl adriamycin-14-valerate. Submitted to Cancer treat. Rep. 1978 Price, L. A., Goldie, J. H., Hill, B. T.: Methodichlorophen as an antitumour drug: preliminary report. Brit. med. J. 2, 20 (1975) Rodriguez, V., Bodey, G. P., Freireich, E. J., McCredie, K. B., McKelvey, E. M., Tashima, C. K.: Reduction of ifosfamide toxicity using dose fractionation. Cancer Res. 36, 2945–2948 (1976) Rozencweig, M., Kenis, Y., Atassi, G., Staquet, M., Duarte-Karim, M.: M.: DNA-Adriamycin complex: preliminary results in animals and man. Cancer Chemother Rep. 6 (Part 3), 131–136 (1975) Saphonova, T. S., Cherov, V. A.: Photrin, a new antitumour agent. Antitumor Drug Therapy Reports 3, 45–46 (1977) Schein, P.: Nitrosoureas. Paper presented at 10th International Congress Chemotherapy, Zürich, September 1977. To be published in 1978 Seeber, S., Meshkov, T., Schmidt, C. G.: Restoration of adriamycin sensitivity in an adriamycin resistant Ehrlich ascites tumour (Abstract 498). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Somfai-Relle, S., Gati, E., Bencze, J., Gal, F.: New derivatives of dianhydrogalactitol (NSC-132313) with significant antitumor activity (Abstract 614). In: Proceedings 10th International Congress Chemotherapy, Zürich, September 1977 Soukop, M., McVie, J. G., Calman, K. C.: Vitamin A status and chemotherapeutic responses in cancer patients (Abstract 590). In: Proceedings 10th International Congress chemotherapy, Zürich, September 1977 Staquet, M., Rozencweig, M., Duarte-Karim, M., Kenis, Y.: Pharmacokinetics of adriamycin and adriamycin-DNA complex in L1210 mice and men. Europ. J. Cancer 13, 433–435 (1977) Syrkin, A. B., Jusktov, S. F., Postolnykov, S. F.: Toxicologic character and some antitumor properties of phytohemagglutinic hanerol. Antitumor Drug Therapy Reports 3, 47–49 (1977) Szekerte, M., Driscoll, J. S.: The use of macromolecules as carries of antitumour drugs. Europ. J. Cancer 13, 529–537 (1977) Szumiel, I., Nias, A. H. W.: The effect of combined treatment with a platinum complex and ionising radiation on chinese hamster ovary cells in vitro. Brit. J. Cancer 33, 450–458 (1976) Taylor, I. W., Bleehen, N. M.: Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Brit. J. Cancer 35, 587–594 (1977) Tillian, H. M., Schauenstein, E., Erth, A., Estebauer, H.: Therapeutic effect if cysteine adducts of α-β-unsaturated aldehydes on Ehrlich ascites tumour of mice. Europ. J. Cancer 12, 989–993 (1976) Trouet, A., Deprez-de Campeneere, D., de Duve, C.: Chemotherapy through lysosomes with a DNA-Daunorubicin complex. Nature (Lond.) New Biol. 239, 110 (1972) Trouet, A., Deprez-de Campeneere, D., de Smedt-Malengreaux M., Atassi, G.: Experimental leukemia chemotherapy with a “lysosomotropic” adriamycin DNA complex. Europ. J. Cancer 10, 405–411 (1974) Valdivieso, M., Bodey, G. P., Gottlieb, J. A., Freireich, E. J.: Clinical evaluation of ftorafur pyrimidine-deoxyribose: N1-2′-furanidyl-5-fluorouracil. Cancer Res. 36, 1821–1824 (1976) Vecchi, A., Cairo, M., Montovani, A., Sironi, M., Sperafico, F.: The comparative antineoplastic activity of adriamycin and N-trifluoroacetyl-adriamycin-14-valerate. Cancer treat. Rep. (in press, 1977) Wardman, P., Adams, G.: Proceedings of the 8th L.H. Gray Meeting on Hypoxic Cell Sensitizers in Radiobiology and Radiotherapy. Brit. J. Cancer (in press, 1978) Wiltshaw, E., Carr, B.: Cis-platinum diammine dichloride: clinical experience of the Royal Marsden Hospital and Institute of Cancer Research, London, pp. 178–182. In: Platinum coordination complexes in cancer chemotherapy (Eds. T. A. Connors and J. J. Roberts). Heidelberg, New York, Berlin: Springer Verlag 1974 Zbinden, G.: Inhibition of adriamycin cardiotoxicity by acetyldaunomycin. Experientia (Basel) 31, 1058–1060 (1975) Zeller, W. J., Eisenbrand, G., Fiebig, H.: Chemotherapeutic activities of new 2-chloroethylnitrosoureas in rat leukaemia L5222. Comparison of bifunctional and water soluble derivatives of BCNU. J. nat. Cancer Inst. (in press, 1977)